Akeso, Inc. (HKG:9926)
Hong Kong · Delayed Price · Currency is HKD 90.25
-3.65 (-3.89%)
Aug 21, 2026, 4:08 PM HKT
Akeso Employees
Akeso had 3,761 employees as of December 31, 2025. The number of employees increased by 726 or 23.92% compared to the previous year.
Employees
3,761
Change
726
Growth
23.92%
Revenue / Employee
904.30K HKD
Profits / Employee
-329.32K HKD
Market Cap
83.13B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3,761 | 726 | 23.92% |
| Jun 30, 2025 | 3,529 | - | - |
| Dec 31, 2024 | 3,035 | 257 | 9.25% |
| Dec 31, 2023 | 2,778 | 437 | 18.67% |
| Dec 31, 2022 | 2,341 | 476 | 25.52% |
| Dec 31, 2021 | 1,865 | 1,119 | 150.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 21,435 |
| WuXi Biologics | 13,252 |
| Innovent Biologics | 7,502 |
| Genscript Biotech | 6,165 |
| 3SBio | 6,109 |
| Shanghai Henlius Biotech | 3,762 |
| RemeGen | 3,048 |
| Shanghai Junshi Biosciences | 2,903 |
Akeso News
- 4 days ago - Summit says Akeso receives marketing authorization in China for ivonescimab - TheFly
- 11 days ago - Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer - PRNewsWire
- 4 weeks ago - Akeso Doses First Patient In Phase II Study Of Novel Bispecific ADC In Advanced NSCLC - Nasdaq
- 5 weeks ago - Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer - PRNewsWire
- 2 months ago - Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026 - PRNewsWire
- 2 months ago - Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio - PRNewsWire
- 2 months ago - An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed. - Market Watch
- 2 months ago - Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's - Reuters